Certara (CERT) announced expected revenue and bookings for the first quarter of 2025 based upon a preliminary review. Revenue is projected to be $106.0 million, compared to $96.7 million in the first quarter of 2024, representing growth of 10%. The company expects bookings of $118.0 million, compared to $105.8 million in the first quarter of 2024, representing growth of 12%. Adjusted EBITDA is expected in the range of $33-$35 million, compared to $29.1 million in the first quarter of 2024, representing growth of 13-20%.
Certara is a New Jersey-based company that provides services such as clinical pharmacology, regulatory writing and decision analytics for biopharmaceutical companies.